Early oral anticoagulation monotherapy after percutaneous coronary intervention (PCI): Insights from the POEM trial
Primary resultResult — go to the resultHazard ratio 0.41 95% CI 0.14–1.22Authors' conclusion
In HBR patients after PCI, transition to OAC monotherapy at 1 month was associated with low ischemic and bleeding risks, comparable to single antiplatelet therapy.
Study context
- Population
- High-bleeding-risk (HBR) patients undergoing PCI with a bioresorbable polymer everolimus-eluting stent, with and without oral anticoagulation (OAC) indication
- Participants
- 281 vs 158
- Comparison
- OAC vs non-OAC
- non-OACn = 281reference
- OACn = 158
- Primary endpoint
- Composite of:
- Cardiac death
- MI
- Definite/probable stent thrombosis
- Follow-up
- 1 year
Methodological detailsprespecified sub-analysis, stratified by OAC indication
- Prespecified sub-analysis
- Stratified by OAC indication
Primary result
As reported in the abstract
Hazard ratio
0.41
95% CI 0.14–1.22
P = 0.097
By group
OAC vs non-OAC
HR 0.41 (95% CI 0.14–1.22); P = 0.097
Further findings
Secondary ischemic outcomes
- Similar in the two groups
Safety
BARC type 3-5 bleeding · 1 year
- BARC type 3-5 bleeding infrequent (non-OAC vs OAC, in the order the abstract reports the groups)
- 2.6% vs 1.3%; P = .369
Original publication
Early oral anticoagulation monotherapy after PCI: Insights from the POEM trial. Am Heart J. Published 19 November 2025. doi:10.
Summarised from the published abstract; every number is checked against it